Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 223

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 12
Chunk 223
---
nification Accruals(1,862)(13,675)13,000 Net cash used in operating activities(68,173)(66,930)(65,045)

The accompanying notes are an integral part of these consolidated financial statements.

F-12

Precigen, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

Years Ended December 31, 2024, 2023, and 2022

(Amounts in thousands)202420232022Cash flows from investing activitiesPurchases of investments(187,206)(185,026)— Sales and maturities of investments175,016 183,377 68,441 Purchases of property, plant and equipment(8,584)(1,536)(4,924)Proceeds from sale of assets60 98 594 Proceeds from sale of discontinued operations— — 162,306 Net cash (used in) provided by investing activities(20,714)(3,087)226,417 Cash flows from financing activitiesProceeds from issuance of common stock , net of issuance costs31,237 72,808 — Payments of long-term debt, including cost to retire of $120 and $588 in 2023 and 2022, respectively— (43,219)(155,293)Proceeds from issuance of Series A Preferred Stock and Warrants79,000 — — Proceeds from stock option exercises346 — 1 Net cash provided by (used in) financing activities110,583 29,589 (155,292)Effect of exchange rate changes on cash, cash equivalents, and restricted cash(27)(320)(827)Net increase (decrease) in cash, cash equivalents, and restricted cash21,669 (40,748)5,253 Cash, cash equivalents, and restricted cashBeginning of year7,848 48,596 43,343 End of year$29,517 $7,848 $48,596 

The accompanying notes are an integral part of these consolidated financial statements.

F-13

Precigen, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

Years Ended December 31, 2024, 2023, and 2022

(Amounts in thousands)202420232022Supplemental disclosure of cash flow informationCash paid during the period for interest$7 $1,171